Product Information
ROPINIROLE HCL ER 12 MG TABLET is a generic product labeled by Solco Healthcare US LLC, priced at $1.8112 per EA under NDC 43547055803. Its NADAC has been published 210 times since Sep 28, 2022.
FDA first approved this application on May 11, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12 mg/1
Manufacturer
Solco Healthcare US LLCNDC
43547055803
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROPINIROLEApproval Type
Generic (ANDA)
FDA Application
ANDA204413FDA Approved
5/11/2022
TE Code
AB
On Market Since
3/22/2022
Pharmacological Classes
Price Statistics
The NADAC for ROPINIROLE HCL ER 12 MG TABLET has been published 210 times since Sep 28, 2022, and over the history we have for it it has risen 13.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8112 per EA |
|---|---|
| All-time high | $2.7115 (Dec 11, 2024) |
| All-time low | $0.8169 (Mar 22, 2023) |
| 52-week high | $2.3685 |
| 52-week low | $1.8112 |
| Median price | $2.0055 |
| Average price | $1.7606 |
| Largest weekly change | +108.5% (Apr 17, 2024) |
| Weeks tracked | 210 |
| Tracking since | Sep 28, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ropinirole market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solco Healthcare US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ropinirole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonergot Dopamine Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROPINIROLE HCL ER 12 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROPINIROLE HCL ER 12 MG TABLET, manufactured by Solco Healthcare US LLC, is $1.8112 per EA (NDC 43547055803), effective Sep 30, 2026.
How has the price of ROPINIROLE HCL ER 12 MG TABLET changed over time?
Over the history we have for it, the NADAC for ROPINIROLE HCL ER 12 MG TABLET has risen 13.2%. It has been tracked across 210 weekly CMS publications since Sep 28, 2022.
What are the highest and lowest recorded NADAC prices for ROPINIROLE HCL ER 12 MG TABLET?
Since Sep 28, 2022, the NADAC for ROPINIROLE HCL ER 12 MG TABLET has ranged from a low of $0.8169 (Mar 22, 2023) to a high of $2.7115 (Dec 11, 2024), with a median of $2.0055 per EA.
Are there cheaper alternatives to ROPINIROLE HCL ER 12 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ROPINIROLE HCL ER 12 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ROPINIROLE HCL ER 12 MG TABLET?
ROPINIROLE HCL ER 12 MG TABLET (NDC 43547055803) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.